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Group versus individual academic detailing to improve
the use of antihypertensive medications in primary care:
a cluster-randomized controlled trial
Steven R. Simon, Sumit R. Majumdar, Lisa A. Prosser, 
Susanne Salem-Schatz, Cheryl Warner, Ken Kleinman, 
Irina Miroshnik, Stephen B. Soumerai
PURPOSE: To compare group versus individual academic detailing to increase diuretic or -blocker
use in hypertension.
METHODS: We conducted a cluster-randomized controlled trial in a large health maintenance
organization. Subjects (N9820) were patients with newly treated hypertension in the year preceding
the intervention (N3692), the 9 months following the intervention (N3556), and the second year
following intervention (N2572). We randomly allocated 3 practice sites to group detailing (N227
prescribers), 3 to individual detailing (N235 prescribers), and 3 to usual care (N319 prescribers).
Individual detailing entailed a physician-educator meeting individually with clinicians to address
barriers to prescribing guideline-recommended medications. The group detailing intervention incorpo-
rated the same social marketing principles in small groups of clinicians.
RESULTS: In the first year following the intervention, the rates of diuretic or -blocker use increased
by 13.2% in the group detailing practices, 12.5% in the individual detailing practices, and 6.2% in the
usual care practices. As compared with usual care practices, diuretic or -blocker use was more likely
in group detailing practices (adjusted odds ratio (OR), 1.40; 95% confidence interval (CI), 1.11 – 1.76)
and individual detailing practices (adjusted OR, 1.30; 95% CI, 0.95 – 1.79). Neither intervention
affected blood pressure control. Two years following this single-visit intervention, there was still a trend
suggesting a persistent effect of individual (OR, 1.22; 95% CI, 0.92 – 1.62), but not group, detailing
(OR, 1.06; 95% CI, 0.80 – 1.39), as compared with usual care.
CONCLUSION: Both group and individual academic detailing improved antihypertensive prescribing 
over and above usual care but may require reinforcement to sustain improvements.
Introduction
Despite the wide dissemination of evidence-based prac-
tice guidelines,1-7 the pharmacologic treatment of hyperten-
sion is suboptimal.8 Many patients with uncomplicated hy-
pertension do not receive a diuretic or -blocker, the
guideline-recommended first-line medications that are rela-
tively inexpensive and have proven superiority in prevent-
ing morbidity and mortality compared with newer classes of
medication, with similar side effect profiles.9-11 In 1996, no
more than 41% of patients with hypertension were taking a
diuretic, -blocker, or both drugs.12 Despite the morbidity
and costs associated with hypertension and its complica-
tions,13,14 there have been few controlled studies of inter-
ventions to improve physicians’ prescribing behavior in
hypertension.15-18
Educational outreach, also called “academic detailing,”19
has been consistently demonstrated to be effective in im-
proving physicians’ prescribing behaviors.20,21 Academic
detailing involves the use of trained “detailers” (usually
physicians or clinical pharmacists) conducting face-to-face
visits with prescribers to encourage adoption of a desired
behavior pattern. Academic detailing has rarely been stud-
ied in the setting of improving the treatment of hyperten-
sion.18 Although academic detailing was originally con-
ceived and proven effective as a one-on-one educational
intervention, several studies have incorporated academic
detailing principles in small group sessions.22-27
In 1995 we conducted a quality improvement project
using the principles of academic detailing to increase the
use of diuretics and -blockers among patients with hyper-
tension. We recently analyzed the effects of this interven-
tion, designed and carried out as a randomized controlled
trial of group versus individual academic detailing, because
the pharmacologic treatment of hypertension continues to
be an area in need of improvement and because the core
recommendations of the intervention – increasing the use of
diuretics and -blockers in uncomplicated hypertension –
remain relevant today.
Methods
Setting and study period
At the time of the study, Harvard Community Health
Plan (HCHP) was a mixed-model HMO serving approxi-
mately 650 000 individuals in 57 medical practices in New
England. HCHP comprised 3 separate administrative divi-
sions, 2 of which were staff-model HMOs, while 1 was a
group-model (also known as an independent-practice asso-
ciation, or IPA-model) HMO. We recruited 3 geographi-
cally separated practices of similar size and demographic
composition from each division.
The study intervention occurred from July to September,
1995. Before undertaking analyses, we classified the 12
months preceding the intervention (July 1994 – June 1995)
as the baseline period and October 1995 – June 1996 as the
initial post-intervention follow-up period for the primary
analysis. We also defined a long-term follow-up period, July
1996 – June 1997, to assess the persistence of effect.
Overall design
We conducted a cluster-randomized controlled trial28 of
3 educational strategies to improve prescribing in hyperten-
sion: individual academic detailing, group academic detail-
ing, and mailed educational materials (“usual care”). Each
experimental arm consisted of 3 practice groups (1 from
each administrative division of the HMO). Practice admin-
istrators, clinicians, and patients were blinded with respect
to study hypotheses. Blinding with respect to the experi-
mental condition was not feasible. The institutional review
boards of Harvard Medical School and of Harvard Pilgrim
Health Care approved the study protocol.
Study patients
All patients with hypertension (either incident or preva-
lent) receiving primary care at one of the 9 study sites were
eligible for analysis. We defined “incident” patients as those
with newly diagnosed and treated hypertension within each
time frame (baseline, initial follow up, long-term follow
up). These patients were determined to have hypertension
on the basis of having at least 2 outpatient encounters or 1
inpatient encounter with a hypertension diagnosis and evi-
dence of a dispensed antihypertensive medication during the
observation period. Thus, each analytic time period had a
different cohort of incident patients. We associated a clini-
cian with each patient by identifying the predominant pre-
scriber of antihypertensive medications for that patient dur-
ing the analytic time period of the patient’s incident
hypertension.
In each time frame, we also identified patients with
prevalent treated hypertension, defined as having at least 2
outpatient encounters or 1 inpatient encounter with a hyper-
tension diagnosis and evidence of a dispensed antihyperten-
sive medication during the 12-month period preceding the
time frame of interest. A subset of prevalent patients in each
time frame included patients who were considered to have
incident treated hypertension in a preceding time frame.
Interventions
All clinicians providing primary care for adults at the 9
study sites were included. Before developing the academic
detailing interventions, we carried out a focus group among
8 practicing physicians from the 3 HCHP administrative
divisions. This 90-minute focus groups consisted of open-
ended discussions to identify potential barriers practicing
physicians perceived when treating hypertension in general
and the advantages and disadvantages of first-line agents
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versus non-preferred agents. Three physician perceptions
emerged as the core barriers to using diuretics or -block-
ers:
1. “Large doses of old drugs, such as -blockers and di-
uretics, fail to control blood pressure, while smaller
doses of new drugs do.”
2 “Older drugs cause more side effects, like impotence,
lethargy, and depression.”
3 “New drugs do lower blood pressure; therefore, long-
term outcomes will be same as older drugs.”
Physicians in the focus group session also expressed
concern that patients would not understand a recommenda-
tion to return to older drugs when the physicians themselves
may have previously discontinued the older drugs in favor
of newer agents, such as ACE inhibitors or calcium-channel
blockers. We developed counterarguments in response to
each of these perceptions and concerns.
We selected 1 respected physician idea champion, or
“peer leader,”29 from each HCHP administrative division to
deliver the group and individual academic detailing sessions
within that division. We conducted a full-day session to
train the detailers, covering the principles of academic de-
tailing, the clinical evidence and guidelines underlying the
recommended prescribing practices, and role-playing. This
session emphasized training the detailers to teach physicians
strategies for talking with patients about starting or switch-
ing to the guideline-recommended agents.
Usual care
In April 1995, clinicians at all 9 practice sites received a
mailing that contained printed material describing the cur-
rent guidelines for prescribing antihypertensive medications
and a laminated wallet card that summarized the guidelines.
Individual academic detailing
From July – September 1995, we conducted one-on-one
educational outreach meetings among primary care physi-
cians at each of the 3 practices randomized to this condition.
The intervention consisted of a single visit (15-30 minutes)
from the trained detailer, incorporating the core principles
and methods of academic detailing, described in detail else-
where.19 These principles included: 1) conducting surveys,
interviews or focus group sessions to investigate baseline
knowledge and motivation for current and proposed pre-
scribing patterns; 2) establishing credibility through a re-
spected organizational sponsor, referencing authoritative
and unbiased information sources, and presenting both sides
of controversial issues; 3) stimulating physician participa-
tion in two-way interaction; 4) using concise and visually
appealing graphical educational materials, specifically ad-
dressing real and perceived barriers to change; and 5) re-
peating and positively reinforcing a small number of desired
behaviors within each detailing encounter. More than 80%
of the full-time primary care physicians at the individual
detailing sites received the intervention.
Group academic detailing
During the intervention period, each of the 3 trained
detailers delivered 45-minute small-group (7-8 clinicians in
attendance) academic detailing sessions at sites randomized
to this condition. Attendance records indicate that approxi-
mately 55% of the clinicians at the group detailing sites
attended these group educational sessions, simply reflecting
the fact that it was logistically more difficult to schedule
group meetings rather than one-to-one visits. The sessions
were designed using the principles of academic detailing
described above.19 In addition, we employed supportive
group processes, such as encouraging individual clinicians
to share success stories in overcoming barriers to adhering
to guideline recommendations and providing clinicians with
an opportunity for mutual reinforcement of desired practice
behaviors.
Outcome measures
We measured prescribing of antihypertensive medica-
tions using the pre-existing pharmacy dispensing (claims)
databases of HCHP. The main outcome measure was
change in guideline adherence (ie, the proportion of patients
with incident hypertension receiving a diuretic or
-blocker). A patient was considered to have received a
diuretic or -blocker if he or she received at least one
prescription for either drug during the specified time frame.
As a secondary outcome measure, we determined whether
each of the patients with prevalent hypertension previously
treated with antihypertensive agents other than diuretics or
-blockers received one of the recommended agents in each
time frame.
Blood pressure measurements were available for patients
seen in the three practices within the one administrative
division of the HMO that had an electronic medical record.
Among patients with incident hypertension in these prac-
tices, we measured the last recorded blood pressure in the
baseline year and in the initial post-intervention period.
We estimated the average per-person cost of antihyper-
tensive medications for incident patients. We determined
the number of patients in each experimental arm who re-
ceived diuretics, -blockers, calcium channel blockers
and/or ACE inhibitors in the baseline year and in the initial
post-intervention period. We multiplied the number of pa-
tients receiving each drug class by the annual cost (to the
health plan) of the most commonly received agent and
dosing strength within each class (ie, hydrochlorothiazide
25 mg for diuretics, atenolol 50 mg for -blockers, nifedi-
pine XL 60 mg for calcium channel blockers, and lisinopril
20 mg for ACE inhibitors), assuming once-daily dosing. We
summed all drug costs in each arm in each year and divided
by the number of people in each group to obtain the annual
antihypertensive drug costs per person.
We used administrative (claims) data to calculate rates of
hospitalization across experimental arms in the pre-inter-
vention and post-intervention years among patients with
incident treated hypertension. In the administrative division
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with an electronic medical record, we also measured outpa-
tient visits. We determined the costs of the interventions
from administrative records and divided these costs by the
number of patients with incident hypertension in the base-
line year to obtain a conservative estimate of intervention
cost per patient.
Covariates
We used automated health plan data to ascertain the
following patient variables: age, sex, insurance type (HMO,
Medicare, Medicaid, fee-for-service), and continuous en-
rollment in the health plan. We determined presence or
absence of diabetes, based on one or more dispensed dia-
betes medications or one inpatient or two outpatient visits
with diabetes codes during each patient’s first year of ob-
servation. We calculated a chronic disease score (CDS) for
each patient based on utilization of drugs for chronic disease
in the first year of the study.30,31 We determined the median
education level and median income of the census tract of
residence for each patient.
We ascertained prescriber variables (age, sex, years in
practice, degree [medical doctor, physician assistant, or
nurse practitioner]) by linking provider names from the
health plan claims data with public data bases.32,33
Statistical analysis
The unit of allocation and the unit of intervention were
the practice. The unit of analysis was the patient. To assess
baseline comparability, we compared intervention and usual
care patients with incident treated hypertension during the
pre-intervention period with regard to the use of antihyper-
tensive medications and other demographic and clinical
variables that may be associated with use of diuretics or
-blockers.
We used logistic regression with generalized estimating
equations (GEE) to estimate the effect of the interventions
on prescribing of first-line agents and to control simulta-
neously for clustering at the level of the physician and for
differences among individual patients.28 In initial models,
we accounted only for clustering by physician. We also
evaluated models that adjusted simultaneously for patient
and prescriber characteristics. In these more detailed anal-
yses, point estimates and confidence intervals did not ma-
terially change; therefore we present only the cluster-ad-
justed estimates. Each model included all patients with
incident, treated hypertension in each study period. In ad-
dition, we used GEE to assess the effect of the interventions
on blood pressure, modeling the dichotomized outcome
(systolic blood pressure  140 mm Hg versus  140 mm
Hg).
All analyses used intention-to-treat principles, such that
clinicians practicing at a site were considered to have been
exposed to the intervention assigned to that site, regardless
of attendance at educational sessions. Similarly, all patients
were analyzed within the intervention arm to which their
predominant prescriber of antihypertensive medications was
assigned.
Results
Table 1 shows the baseline demographic and clinical
characteristics of patients with incident treated hyperten-
sion. The rates of use of diuretics or -blockers across the
3 arms were almost identical, as were the age and sex
distributions and average chronic disease scores. Table 2
describes the characteristics of the primary care clinicians
within each experimental condition.
Intervention effects: incident patients
Figure 1 shows the absolute increases in the proportion
of newly diagnosed and treated hypertension patients re-
ceiving diuretics or -blockers within each experimental
group in the first year and in the second year of follow up.
In the first year following the intervention, rates of use of
diuretics or -blockers increased by 13.2% in the group
academic detailing practices, 12.5% in the individual detail-
ing practices, and 6.2% in the mailed practice guideline
(usual care) practices. These absolute increases correspond
to proportional increases of 22.3% (group detailing), 21.7%
(individual detailing), and 10.8% (usual care) as compared
with the baseline rates.
Relative to usual care practices, diuretic or -blocker use
was more likely in group detailing practices (OR, 1.40; 95%
CI, 1.11 – 1.76) and individual detailing practices (OR,
1.30; 95% CI, 0.95 – 1.79), after controlling for physician-
level clustering. The effects of group and individual detail-
ing were of similar magnitude (OR for group versus indi-
vidual detailing, 1.10; 95% CI, 0.86 – 1.42).
In the second year following the intervention, the abso-
lute increase in use of the guideline-recommended agents
over baseline was greater in the individual detailing prac-
tices (14.7%) than in the group detailing practices (11.3%)
or the usual care practices (10.1%) (Figure 1). During the
second year following the intervention, 72.3% of patients in
the individual detailing practices received diuretics or
-blockers, as compared with 70.4% in the group detailing
practices and 67.7% in the mailed guideline practices. Al-
though not statistically significant, our data suggest that 2
years after the interventions, there was a trend suggestive of
a persistent effect of individual detailing (OR, 1.22; 95% CI,
0.92 – 1.62), but not group detailing (OR, 1.06; 95% CI,
0.80 – 1.39).
The intervention appeared to have no clinically mean-
ingful effect on blood pressure control. The mean systolic
blood pressures pre- and post-intervention in the 3 practice
sites in which these measurements were available are shown
in Figure 2. As compared with the patients in the mailed
guideline practice, patients in the individual detailing prac-
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tice were slightly but not significantly less likely to have
systolic blood pressure less than 140 mmHg in the first year
following intervention (OR, 0.87; 95% CI, 0.55 – 1.39).
Patients in the group detailing practice and those in the
mailed guideline practice had similar probability of achiev-
ing this level of blood pressure control (OR, 0.98; 95% CI,
0.65 – 1.49).
Intervention effects: prevalent patients
There was no effect of either detailing intervention on
switching patients with prevalent and treated hypertension
to either diuretics or -blockers. As compared with the
mailed guideline practices, the odds ratio for switching to
diuretics or -blockers was 1.20 in the individual detailing
practices (95% CI, 0.76 – 1.90) and 1.35 in the group
detailing practices (95% CI, 0.89 – 2.06).
Considering incident patients who received a diuretic or
-blocker in the baseline year, 83% of patients in the indi-
vidual detailing practices and 77% of patients in the group
detailing practices remained on diuretics or -blockers in
the first year following the intervention, compared with
74% in the mailed guideline practices.
Costs of antihypertensive medications,
intervention costs, and utilization
The estimated average per-person costs of antihyperten-
sive medications in the baseline year were $288 in the
mailed guideline practices, $277 in the individual detailing
practices, and $269 in the group detailing practices. In the
year following intervention, the per-person costs decreased
to $219 in the mailed guideline practices, $198 in the indi-
vidual detailing practices, and $220 in the group detailing
practices. The per-patient reductions in medication costs
were therefore $69 in the mailed guideline practices, $79 in
the individual detailing practices, with a $1 per patient
increase in the group detailing practices.
The overall intervention costs were $1000 for the mailed
guideline intervention (approximately $1 per patient),
Table 1 Baseline demographic and clinical characteristics of patients with newly treated hypertension in the baseline year (N 









Male 51.4 52.6 50.2
Female 48.6 47.4 49.9
Age, %
 45 years 18.8 20.3 24.4
45–54 years 29.3 27.6 30.3
55–64 years 25.5 26.5 22.1
65–74 years 18.2 16.7 15.7
 75 years 8.3 8.9 7.5
High school education, %* 98.2 99.4 94.5
Median household income
25th percentile $40 057 $33 734 $30 122
Median $50 364 $40 888 $38 906
75th percentile $65 674 $52 579 $47 552
Insurance type
HMO 75.7 77.9 77.4
Medicare 20.0 18.2 17.4
Other† 4.3 4.0 5.2
Continuous health plan enrollment, % 76.5 78.2 73.3
Diabetes, % 9.4 10.7 12.7
Chronic disease score,‡ mean (sd) 893.2 (611) 890.1 (575.1) 899.4 (652.7)
Rates of antihypertensive medication
use§
-blockers, % 37.2 34.9 33.9
Diuretics, % 28.7 32.3 32.2
-blockers or diuretics, % 57.6 59.1 57.6
ACE inhibitors or ARB, % 46.8 42 46.2
Calcium-channel blockers, % 27.1 30.8 31.7
Other antihypertensive agents, % 6.4 6.6 6.1
Abbreviations: AD  academic detailing; HMO  health maintenance organization; ARB  angiotensin-receptor blocker; sd  standard deviation.
*Education level was missing for 111 patients who were under age 25 years.
†Includes Medicaid and indemnity insurance plans.
‡See description in text.
§Overall rates of antihypertensive medication use sum to greater than 100% because some patients were taking multiple medications.
    5
$3500 ($3.50 per patient) for group detailing, and $5000 ($5
per patient) for individual detailing.
Table 3 shows the rates of hospitalization and office
visits within the experimental conditions.
Discussion
Few controlled studies have demonstrated improvements
in the pharmacologic management of hypertension outside
clinical trials.16,18 This study found that both individual and
group academic detailing were effective in improving the
initial pharmacologic treatment of hypertension. Both de-
tailing interventions resulted in approximately 13% absolute
increases (or 20% relative increases) in the use of guideline-
recommended agents for patients with newly treated hyper-
tension, as compared with usual care. Our data suggest that
the increased use of guideline-adherent therapies did not
affect blood pressure control.
By the second year following the single-visit interven-
tions, the effects of both group detailing and individual
detailing had decayed. There was a nonsignificant trend
toward a persistent effect in the individual detailing arm but
not in the group detailing arm. To date, few studies have
demonstrated the persistence of the effect of academic de-
tailing beyond the first 6-12 months following interven-
tion.34 It is likely that a reinforcement session of some type
would be necessary to maintain changes in behavior and,
possibly, to engage physicians not captured in the initial
session.
Neither detailing intervention resulted in any effect on
switching patients to diuretics or -blockers. Engaging phy-
sicians to switch patients’ therapies likely requires more
intensive intervention strategies than a single educational
outreach visit.
Both group and individual academic detailing have been
shown in prior studies to produce, on average, 15-30%
relative increases over baseline in the desired clinical be-
havior.21,23,27 We observed effects of similar magnitude in
the present study.
Because diabetes may be treated with ACE inhibitors as
the first-line agent, we controlled for this condition in the
main analyses and this is thus unlikely to confound our
observed effects.
A full economic analysis of the costs and cost-savings
related to the academic detailing interventions is beyond the
scope of this study. Nevertheless, our observations indicate
that the group detailing intervention ($3500) cost less than
the individual detailing intervention ($5000) and that these
intervention costs were of the same magnitude as the med-
ication cost savings.
This study has several limitations. First, it was conducted
in a single managed care organization, which limits the
generalizability of the findings. However, this setting was a
mixed-model HMO, including both staff- and group-model
divisions. Furthermore, the large majority of health care in
Figure 1 Absolute increases in rates of use of -blockers or
diuretics among newly treated patients with hypertension. Year 1
indicates the first 9 months following the 3-month intervention
period. Year 2 indicates the 12-month period following Year 1.
Figure 2 Average systolic blood pressures among patients with
incident treated hypertension.
Table 2 Baseline characteristics of prescribing clinicians









Male 57 70 62.5
Female 43 30 37.5
Years of Practice,* %
 10 25.3 21.3 22.1
10–20 48.1 44.7 51.0
21 26.6 34.0 26.9
Degree,* % (n  276)
M.D. 65.8 72.3 74.8
P.A. or N.P. 34.2 27.7 25.2
Abbreviations: AD  academic detailing; P.A.  physician assis-
tant; N.P.  nurse practitioner.
*Data on sex and years of practice were available for 277 of the 367
prescribers. The degree was known for 276 of the 367 prescribers.
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the United States is delivered via managed care plans, the
enrollment of which currently exceeds 200 million.35
Second, baseline adherence rates (58-59%) were sub-
stantially higher than national figures from the same time
period.12 We did not target the intervention to clinicians
whose prescribing patterns indicated greater potential for
improvement, one of the original core principles of aca-
demic detailing.19 Such targeting would likely have in-
creased the observed effects of the academic detailing in-
terventions.
Finally, although some may consider the age of our data
to be the most important limitation of this study, the core
guideline recommendations for diuretics and -blockers as
first-line agents in hypertension have remained unchanged.
Despite more than 25 years of widely circulated guide-
lines for care of patients with high blood pressure,1 evi-
dence-based treatment of hypertension continues to elude a
large segment of clinical practice in the United States. We
found that both individual and group academic detailing can
increase the use of guideline-based treatments in hyperten-
sion. Further study is needed to understand the economic
ramifications of expanding this kind of intervention to im-
prove the care of hypertension and other chronic diseases.







Hospitalizations per patient, mean (sd)
Baseline (N  3692) 0.26 (0.79) 0.25 (0.77) 0.26 (0.94)
Follow-up Year 1 (N  2142) 0.18 (0.63) 0.22 (0.69) 0.21 (0.79)
Outpatient visits per patient, mean (sd)
Baseline (N  1534) 9.36 (7.26) 10.22 (7.84) 10.37 (12.47)
Follow-up Year 1 (N  811) 10.03 (8.30) 9.37 (7.48) 8.50 (6.61)
Abbreviation: sd  standard deviation.
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